942920-55-0

Basic information

• Product Name: ethyl 4-bromo-1H-pyrrolo[2,3-b]pyridine-2-carboxylate
• Synonyms: ethyl 4-bromo-1H-pyrrolo[2,3-b]pyridine-2-carboxylate;3-b]pyridine-2-carboxylate;ethyl 4-broMo-1H-pyrrolo[2;ethyl 6-chloro-1H-pyrrolo[2;1H-Pyrrolo[2,3-b]pyridine-2-carboxylic acid, 4-broMo-, ethyl ester
• CAS NO: 942920-55-0
• Molecular Formula: C₁₀H₉BrN₂O₂
• Molecular Weight: 269.09
• Product Categories: CHIRAL CHEMICALS;Heterocycle-Pyridine series
• Mol File: 942920-55-0.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Density: 1.624±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 10.96±0.40(Predicted)
• CAS DataBase Reference: ethyl 4-bromo-1H-pyrrolo[2,3-b]pyridine-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-bromo-1H-pyrrolo[2,3-b]pyridine-2-carboxylate(942920-55-0)
• EPA Substance Registry System: ethyl 4-bromo-1H-pyrrolo[2,3-b]pyridine-2-carboxylate(942920-55-0)

Safety Data

• Hazardous Substances Data: 942920-55-0(Hazardous Substances Data)

Usage

General Description

Ethyl 4-bromo-1H-pyrrolo[2,3-b]pyridine-2-carboxylate is a chemical compound with the molecular formula C11H9BrN2O2. It is a pyrrolopyridine derivative, containing a bromine atom and an ester functional group. ethyl 4-bromo-1H-pyrrolo[2,3-b]pyridine-2-carboxylate is commonly used as a building block in the synthesis of various pharmaceutical and agrochemical products. Its unique structure and reactivity make it a valuable intermediate in organic synthesis, particularly in the development of new drugs and crop protection chemicals. It is known for its potential biological activities and is often studied for its pharmacological properties.

Upstream product

• 348640-06-2 4-bromo-7-azaindole 
• 889939-25-7 1-(benzenesulfonyl)-4-bromo-1H-pyrrolo[2,3-b]pyridine 
• 221675-35-0 1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid ethyl ester 
• 287384-82-1 ethyl 1H-pyrrolo[2,3-b]pyridine-2-carboxylate-7-oxide 

Downstream Products

• 945865-21-4 ethyl 4-(4,4,5,5-tetramethyl-1,3,2-diozaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine-2-carboxylate 
• 1234616-71-7 4-bromo-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid 
• 942920-54-9 4-[1-ethyl-3-(4-nitrophenyl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]-pyridine-2-carboxylic acid 
• 1021950-41-3 ethyl 4-[(4-nitrophenyl)amino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylate 

Relevant articles and documents

DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS

The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.

Discovery of GSK1070916, a potent and selective inhibitor of aurora B/C kinase

The Aurora kinases play critical roles in the regulation of mitosis and are frequently overexpressed or amplified in human tumors. Selective inhibitors may provide a new therapy for the treatment of tumors with Aurora kinase amplification. Herein we describe our lead optimization efforts within a 7-azaindole-based series culminating in the identification of GSK1070916 (17k). Key to the advancement of the series was the introduction of a 2-aryl group containing a basic amine onto the azaindole leading to significantly improved cellular activity. Compound 17k is a potent and selective ATP-competitive inhibitor of Aurora B and C with Ki* values of 0.38 ± 0.29 and 1.5 ± 0.4 nM, respectively, and is >250-fold selective over Aurora A. Biochemical characterization revealed that compound 17k has an extremely slow dissociation half-life from Aurora B (>480 min), distinguishing it from clinical compounds 1 and 2. In vitro treatment of A549 human lung cancer cells with compound 17k results in a potent antiproliferative effect (EC50 = 7 nM). Intraperitoneal administration of 17k in mice bearing human tumor xenografts leads to inhibition of histone H3 phosphorylation at serine 10 in human colon cancer (Colo205) and tumor regression in human leukemia (HL-60). Compound 17k is being progressed to human clinical trials.

NOVEL COMPOUNDS

The present invention relates to compounds of formula (I): and processes for preparing them, compositions containing them and their use in treating diseases relating to inappropriate c-Met activity.